Clinical Trials Logo

Parkinson's Disease clinical trials

View clinical trials related to Parkinson's Disease.

Filter by:

NCT ID: NCT00451633 Withdrawn - Parkinson's Disease Clinical Trials

The Effect Of E2007 On Pharmacodynamic Responses To Levodopa Among Patients With Parkinson's Disease Who Experience Dyskinesia And Motor Fluctuations

Start date: March 2007
Phase: Phase 2
Study type: Interventional

A randomized, double blind, placebo-controlled study employing a mixed parallel group and fixed sequence cross-over design. Patients will be randomized to one of two treatment groups ('E2007' or 'Placebo') in a 1:1 ratio and receive investigational drug treatment concomitant with their standard individualized anti-Parkinsonian therapy for a total of six weeks. Investigational drug treatment for patients in the E2007 treatment group will be started 2 mg E2007 o.d. but will be escalated to 4 mg E2007 o.d. after three weeks.

NCT ID: NCT00393562 Withdrawn - Parkinson's Disease Clinical Trials

Comparison of Modafinil and Methylphenidate in Treatment of Excessive Daytime Sleepiness in Patients With Parkinson's Disease

Start date: March 2006
Phase: N/A
Study type: Interventional

This is an open-label cross-over randomized control study comparing the effect of modafinil and methylphenidate in patients with Parkinson's disease with excessive daytime sleepiness.

NCT ID: NCT00327301 Withdrawn - Parkinson's Disease Clinical Trials

Cellular Proteome From Leukocytes of Glaucoma Patients in Comparison With Patients With Parkinson's Disease

Start date: October 2006
Phase: N/A
Study type: Observational

Glaucoma is a worldwide leading cause of blindness. The key feature of this ocular neuropathy is characterized by an excavating optic nerve head. Loss of retinal ganglion cells is the final end point in blinding diseases of the optic nerve such as glaucoma. It is known that neuronal cell death in glaucoma occurs by an apoptotic mechanism. In earlier studies the investigators could demonstrate that the process of apoptosis is reflected in circulating leukocytes by different parameters, like differential mRNA expression and an increased fragmentation of the DNA. Such alterations point out a relationship between cellular stress and apoptotic events. Based on the results of mRNA-expression the investigators also expect alterations on the protein level. This study is, therefore, designed to characterize the proteome related to the proteins involved in cell death related pathways. Thus, the expression pattern of several proteins in leukocytes from patients with primary open angle glaucoma will be analyzed by techniques like Western-blot and tandem mass spectrometry. These samples will be compared with samples from healthy controls. In addition, they will also be compared with samples from patients with Parkinson's disease. Since glaucoma is a neurodegenerative disease, these patients will be included as positive controls in this study.